|
|
|
| Liver transplantation for liver failure in kidney transplantation recipients with hepatitis B virus infection |
| Peng-Peng Zhang a , b , Xing-Guo She a , b , Ke Cheng a , b , Hong Liu a , b , Ying Niu a , b , Ying-Zi Ming a , b , ∗ |
a Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, China
b Engineering & Technology Research Center for Transplantation Medicine of National Ministry of Health, Changsha 410013, China
∗ Corresponding author at: Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, China
E-mail address: myz_china@aliyun.com (Y.-Z. Ming). |
|
|
|
|
Abstract Worldwide, approximately 400 million patients have chronic hepatitis B virus (HBV) infection [1] . Because of the high incidence of HBV in China, the incidence of HBV infection in uremia and kidney transplantation (KTx) patients is 2.5% and 2.7%, respectively [2] . Since the first successful organ transplant conducted between twins in 1954, refined surgical techniques, improved immunosuppressive protocols, and improved perioperative management of transplant patients have resulted in improved patient and graft survivals following K Tx [3] . However, the K Tx community is now challenged with liver failure due to the increased risk of HBV viral activation and replication induced by immunosuppressive therapy. Harnett et al. [4] highlighted that KTx recipients with HBV infection had lower 5-year survival (61%) than patients on dialysis (85%). Although these KTx recipients were treated with regular anti-HBV therapy, the incidence of liver failure was increased in KTx patients with HBV infection. Currently, isolated liver transplantation (LTx), sequential liver and kidney transplantation (SLKT), and combined liver and kidney transplantation (CLKT) are the optimal treatments for patients with liver failure and hepatorenal syndrome [5] . However, the outcomes of KTx recipients following isolated LTx, SLKT or CLKT for HBV-associated liver failure remain to be studied. Herein, we report our experience in ten HBV-positive KTx recipients with liver failure undergoing LTx.
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
